DK1150746T3 - Anvendelse af 4-H-1-benzopyran-4-onderivater som inhibitorer af proliferation af glat muskelcelle - Google Patents

Anvendelse af 4-H-1-benzopyran-4-onderivater som inhibitorer af proliferation af glat muskelcelle

Info

Publication number
DK1150746T3
DK1150746T3 DK00909918T DK00909918T DK1150746T3 DK 1150746 T3 DK1150746 T3 DK 1150746T3 DK 00909918 T DK00909918 T DK 00909918T DK 00909918 T DK00909918 T DK 00909918T DK 1150746 T3 DK1150746 T3 DK 1150746T3
Authority
DK
Denmark
Prior art keywords
benzopyran
inhibitors
derivatives
sub
cell proliferation
Prior art date
Application number
DK00909918T
Other languages
Danish (da)
English (en)
Inventor
Jennifer A Dumont
Winston Campbell Patterson
Original Assignee
Aventis Pharma Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc, Univ Texas filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK1150746T3 publication Critical patent/DK1150746T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00909918T 1999-02-01 2000-01-18 Anvendelse af 4-H-1-benzopyran-4-onderivater som inhibitorer af proliferation af glat muskelcelle DK1150746T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24338099A 1999-02-01 1999-02-01
US09/468,665 US6399633B1 (en) 1999-02-01 1999-12-21 Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
EP00909918A EP1150746B1 (de) 1999-02-01 2000-01-18 Verwendung von 4-h-1-benzopyran-4-on-derivaten als inhibitoren der proliferation von glatten muskelzellen
PCT/US2000/001104 WO2000044362A2 (en) 1999-02-01 2000-01-18 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation

Publications (1)

Publication Number Publication Date
DK1150746T3 true DK1150746T3 (da) 2005-01-10

Family

ID=22918541

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00909918T DK1150746T3 (da) 1999-02-01 2000-01-18 Anvendelse af 4-H-1-benzopyran-4-onderivater som inhibitorer af proliferation af glat muskelcelle

Country Status (38)

Country Link
US (1) US6399633B1 (de)
EP (1) EP1150746B1 (de)
JP (1) JP4755759B2 (de)
KR (1) KR100793047B1 (de)
CN (1) CN1219556C (de)
AP (1) AP1469A (de)
AR (1) AR042569A1 (de)
AT (1) ATE275428T1 (de)
AU (1) AU777368B2 (de)
BG (1) BG65151B1 (de)
BR (1) BR0007911A (de)
CA (1) CA2360668C (de)
CR (1) CR6448A (de)
CZ (1) CZ300395B6 (de)
DE (1) DE60013555T2 (de)
DK (1) DK1150746T3 (de)
EA (1) EA004786B1 (de)
EE (1) EE04851B1 (de)
ES (1) ES2226792T3 (de)
HK (1) HK1042445B (de)
HR (1) HRP20010521A2 (de)
HU (1) HU229263B1 (de)
ID (1) ID30180A (de)
IL (1) IL144668A (de)
ME (1) MEP10508A (de)
NO (1) NO330512B1 (de)
NZ (1) NZ512822A (de)
OA (1) OA11755A (de)
PL (1) PL197693B1 (de)
PT (1) PT1150746E (de)
RS (1) RS50242B (de)
SI (1) SI1150746T1 (de)
SK (1) SK286747B6 (de)
TR (1) TR200102223T2 (de)
TW (1) TWI273907B (de)
UA (1) UA73110C2 (de)
WO (1) WO2000044362A2 (de)
ZA (1) ZA200105596B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102480D0 (en) * 2001-01-31 2001-03-14 Cyclacel Ltd Marker
PL211300B1 (pl) * 2002-04-17 2012-05-31 Cytokinetics Inc Związek i kompozycja zawierająca ten związek
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040082613A1 (en) * 2002-06-28 2004-04-29 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
AU2003273299B2 (en) * 2002-09-05 2010-04-01 Medimmune, Llc Methods of preventing or treating cell malignancies by administering CD2 antagonists
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
JP4934426B2 (ja) 2003-08-18 2012-05-16 メディミューン,エルエルシー 抗体のヒト化
EP2422811A2 (de) 2004-10-27 2012-02-29 MedImmune, LLC Modulation von Antikörperspezifität mittels Anpassung der Affinität zu verwandten Antigenen
EP1869192B1 (de) 2005-03-18 2016-01-20 MedImmune, LLC Rahmenmischung von antikörpern
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
CA2617728A1 (en) * 2005-07-15 2007-01-25 Sahajanand Biotech Private Limited Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis
JP2008255008A (ja) * 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
AU2006275514B2 (en) * 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US8058402B2 (en) 2006-08-28 2011-11-15 Kyowa Hakko Kirin Antagonistic human LIGHT-specific human monoclonal antibodies
CA2676984C (en) 2007-02-01 2015-03-17 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US20110130544A1 (en) 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
KR101892987B1 (ko) 2009-04-22 2018-08-30 리스버로직스 코퍼레이션 신규한 소염제
US20130225530A1 (en) 2010-07-12 2013-08-29 Dkfz Deutsches Krebsforschungszentrum Wogonin for the prevention and therapy of cardiac hypertrophy
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
SG11201500489YA (en) 2012-07-25 2015-02-27 Kolltan Pharmaceuticals Inc Anti-kit antibodies and uses thereof
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
EP2935253B1 (de) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Neuartige heterocyclische verbindungen als bromdomänenhemmer
SG10201708143QA (en) 2013-06-06 2017-11-29 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
US9475874B2 (en) 2013-08-26 2016-10-25 MabVax Therapeutics, Inc. Nucleic acids encoding human antibodies to sialyl-lewisa
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102226248B1 (ko) 2014-06-04 2021-03-12 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 gd2에 대한 사람 단클론 항체
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
BR112017015880A2 (pt) 2015-03-03 2018-07-31 Kymab Ltd anticorpos, usos e métodos
CA2977308A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
CN107995863A (zh) 2015-04-20 2018-05-04 特雷罗药物股份有限公司 通过线粒体分析预测对阿伏西地的应答
AU2016264212B2 (en) 2015-05-18 2020-10-22 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
WO2017024073A1 (en) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
WO2017096051A1 (en) 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CN109803684B (zh) 2016-08-23 2022-08-23 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
SG11201908531WA (en) 2017-03-16 2019-10-30 Eisai R&D Man Co Ltd Combination therapies for the treatment of breast cancer
EP3630834A1 (de) 2017-05-31 2020-04-08 STCube & Co., Inc. Verfahren zur behandlung von krebs mit antikörpern und molekülen, die immunspezifisch an btn1a1 binden
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista
EP3890749A4 (de) 2018-12-04 2022-08-03 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9-inhibitoren und polymorphe davon zur verwendung als mittel zur behandlung von krebs
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CN113559244B (zh) * 2021-08-02 2023-12-26 华中科技大学同济医学院附属协和医院 Ctrp13脂肪因子的新用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (de) * 1986-04-11 1989-02-04 Hoechst India
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
JP2001509805A (ja) 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー 細胞増殖阻害剤としてのピリド〔2,3−d〕ピリミジンおよび4−アミノピリミジン

Also Published As

Publication number Publication date
OA11755A (en) 2005-07-19
TR200102223T2 (tr) 2004-12-21
NZ512822A (en) 2005-01-28
EE04851B1 (et) 2007-06-15
HU229263B1 (en) 2013-10-28
YU54401A (sh) 2004-05-12
NO330512B1 (no) 2011-05-09
PT1150746E (pt) 2004-12-31
IL144668A0 (en) 2002-05-23
RS50242B (sr) 2009-07-15
AP1469A (en) 2005-09-26
TWI273907B (en) 2007-02-21
BG105751A (en) 2002-02-28
BG65151B1 (bg) 2007-04-30
DE60013555T2 (de) 2005-09-29
EP1150746A2 (de) 2001-11-07
HUP0200804A3 (en) 2004-03-29
EA200100742A1 (ru) 2001-12-24
CN1338958A (zh) 2002-03-06
CZ300395B6 (cs) 2009-05-06
NO20013335D0 (no) 2001-07-05
CR6448A (es) 2004-03-17
SI1150746T1 (en) 2005-02-28
HUP0200804A2 (hu) 2002-12-28
AP2001002218A0 (en) 2001-09-30
CA2360668A1 (en) 2000-08-03
AU777368B2 (en) 2004-10-14
EA004786B1 (ru) 2004-08-26
US6399633B1 (en) 2002-06-04
CA2360668C (en) 2009-03-17
WO2000044362A2 (en) 2000-08-03
ID30180A (id) 2001-11-08
KR100793047B1 (ko) 2008-01-10
ZA200105596B (en) 2002-10-07
PL197693B1 (pl) 2008-04-30
PL350735A1 (en) 2003-01-27
MEP10508A (en) 2010-06-10
CZ20012804A3 (cs) 2002-08-14
AR042569A1 (es) 2005-06-29
AU3209800A (en) 2000-08-18
KR20010093309A (ko) 2001-10-27
EP1150746B1 (de) 2004-09-08
IL144668A (en) 2005-06-19
DE60013555D1 (de) 2004-10-14
SK10862001A3 (sk) 2002-07-02
SK286747B6 (sk) 2009-04-06
EE200100385A (et) 2002-12-16
WO2000044362A3 (en) 2001-04-05
CN1219556C (zh) 2005-09-21
ATE275428T1 (de) 2004-09-15
JP4755759B2 (ja) 2011-08-24
ES2226792T3 (es) 2005-04-01
JP2002535356A (ja) 2002-10-22
HK1042445A1 (en) 2002-08-16
UA73110C2 (en) 2005-06-15
BR0007911A (pt) 2001-10-16
NO20013335L (no) 2001-09-25
HRP20010521A2 (en) 2002-08-31
HK1042445B (zh) 2006-01-13

Similar Documents

Publication Publication Date Title
DK1150746T3 (da) Anvendelse af 4-H-1-benzopyran-4-onderivater som inhibitorer af proliferation af glat muskelcelle
DK1351958T3 (da) Imidazol-5-yl-2-anilinopyrimidiner som midler til inhibering af celleproliferation
DK1183033T3 (da) Pyrrolotriazininhibitorer af kinaser
DK1315694T3 (da) Inhibitorer af alpha-4-medieret celleadhæsion
DK1501508T3 (da) Inhibitorer af histondeatylase
DK1181269T3 (da) Celleproliferationsinhibitorer
NO20022649L (no) Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
DK1362582T3 (da) Overtrukket fast doseringsform
DK1563061T3 (da) Dyrkning af hårinducerende celler
DE60306259D1 (de) Auswuchtgerät
DE60311003D1 (de) Fussgelenkstütze
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
DK1144425T3 (da) Derivater af monosaccharider som celleadhæsionsinhibitorer
DE60334690D1 (de) Energiewandler
DK1335130T3 (da) Darrieus-vindmölle
DE60319277D1 (de) Beschichtungszusammensetzung
DK0830345T3 (da) Styryl-benzimidazol-derivater som inhibitorer af glatmuskel-celleproliferation
BRPI0311588A2 (pt) revestimento
DK0981365T3 (da) Leptin som en inhibitor af tumorcelleproliferation
DK1307455T3 (da) Inhibitorer af alpha-L-beta-2-medieret celleadhæsion
DK1181271T3 (da) Naphthalenurinstoffer som inhibitorer af glucoseoptagelse
ITUD20020028A1 (it) Piatto doccia
ITUD20020007U1 (it) Piatto per doccia
FI20021971A0 (fi) Soittimen muunnin